Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
01:11pm, Monday, 27'th Oct 2025
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Exelixis (EXEL) is a Strong Value Stock
10:41am, Monday, 27'th Oct 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
10:00am, Thursday, 23'rd Oct 2025
NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to c
Sequoia Financial Advisors LLC Purchases New Position in Exelixis, Inc. $EXEL
05:22am, Thursday, 23'rd Oct 2025
Sequoia Financial Advisors LLC purchased a new stake in Exelixis, Inc. (NASDAQ: EXEL) in the undefined quarter, according to its most recent filing with the SEC. The institutional investor purchased 6
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
04:05pm, Tuesday, 21'st Oct 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after the markets close. At
Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results
10:48am, Monday, 20'th Oct 2025
Exelixis Inc. (NASDAQ:EXEL) stock is trading lower on Monday after the company shared detailed results from the STELLAR-303 Phase 3 trial.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizu
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX® (cabozantinib) versus place
The Ultimate Biotech Stock to Buy With $50 Right Now
07:30am, Tuesday, 14'th Oct 2025
Finding great biotech stocks to invest in at a price point of $50 per share (or less) isn't easy. There are plenty of companies in the industry trading for far less money than that, but they tend to b
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
10:40am, Thursday, 09'th Oct 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
10:50am, Wednesday, 08'th Oct 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
04:10am, Tuesday, 30'th Sep 2025
Every investor wants to outperform the market, but it's a challenging feat to achieve. That's why few manage to do it consistently over long periods.
Exelixis, Inc. (EXEL) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
12:33pm, Wednesday, 24'th Sep 2025
Exelixis, Inc. (NASDAQ:EXEL ) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 8:50 AM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Partic
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
10:00am, Saturday, 13'th Sep 2025
NEW YORK , Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
02:50pm, Wednesday, 10'th Sep 2025
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors
